Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis

Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis

ABSTRACT Background Blinding mitigates bias in randomized trials and may be especially crucial for surrogate endpoints, such as progression‐free survival (PFS). Here, we characterize utilization of and factors associated with blinding in Phase III oncology trials with PFS primary endpoints. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabrielle Brown, Pavlos Msaouel, Avital M. Miller, Ramez Kouzy, Timothy A. Lin, Joseph Abi Jaoude, Ethan B. Ludmir, Alexander D. Sherry
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Medicine
Subjects:
bias
blinded independent central review
double‐blind
oncology
Phase III
randomized trials
Online Access:https://doi.org/10.1002/cam4.71097
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.71097

Similar Items